Reducing the impact of migraine on functioning: Results from the STRIVE trial, a phase 3, randomised, double-blind, placebo-controlled study of erenumab in patients with episodic migraine

被引：0
|
作者：
Buse, Dawn C. [1 ,2 ]
Lipton, Richard B. [1 ,2 ]
Mikol, Daniel D. [3 ]
Thach, Andrew V. [3 ]
Desai, Pooja [3 ]
Picard, Hernan [3 ]
Kubo, Yumi [3 ]
Hareendran, Asha [4 ]
Kawata, Ariane K. [5 ]
机构：
[1] Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10467 USA
[2] Montefiore Med Ctr, 111 E 210th St, Bronx, NY 10467 USA
[3] Amgen Inc, Thousand Oaks, CA 91320 USA
[4] Evidera, London, England
[5] Evidera, Bethesda, MD USA
来源：
JOURNAL OF HEADACHE AND PAIN | 2017年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P98
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Use of Acute Headache and Migraine Medications in Patients with Episodic Migraine in the STRIVE Phase 3 Trial of Erenumab for Migraine Prevention
    Reuter, Uwe
    Bonner, Jo
    Broessner, Gregor
    Hallstrom, Yngve
    Picard, Hernan
    Cheng, Sunfa
    Zhang, Feng
    Mikol, Daniel
    Klatt, Jan
    NEUROLOGY, 2018, 90
  • [22] Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial
    Croop, Robert
    Lipton, Richard B.
    Kudrow, David
    Stock, David A.
    Kamen, Lisa
    Conway, Charles M.
    Stock, Elyse G.
    Coric, Vladimir
    Goadsby, Peter J.
    LANCET, 2021, 397 (10268): : 51 - 60
  • [23] Impact of Fremanezumab on Disability Severity in Patients With Episodic and Chronic Migraine: Pooled Results of 3 Randomized, Double-blind, Placebo-controlled Phase 3 Studies
    Nagy, Abraham J.
    McAllister, Peter
    Cohen, Joshua M.
    Ning, Xiaoping
    Campos, Verena Ramirez
    Du, Evelyn
    Ashina, Messoud
    NEUROLOGY, 2021, 96 (15)
  • [24] Early Efficacy in Patients ≥60 Years of Age With Episodic or Chronic Migraine: Pooled Results of 3 Randomised, Double-blind, Placebo-controlled Phase 3 Studies
    Holle-Lee, D.
    Cohen, J. M.
    Ning, X.
    Krasenbaum, L. J.
    Yang, R.
    Pozo-Rosich, P.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 162 - 162
  • [25] IMPACT OF FREMANEZUMAB ON DISABILITY SEVERITY IN PATIENTS WITH EPISODIC AND CHRONIC MIGRAINE: POOLED RESULTS OF 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDIES
    Nagy, Abraham J.
    McAllister, Peter
    Cohen, Joshua M.
    Ning, Xiaoping
    Campos, Verena Ramirez
    Du, Evelyn
    Ashina, Messoud
    CEPHALALGIA, 2020, 40 : 93 - 94
  • [26] A double-blind placebo-controlled trial of nabumetone in the prophylaxis of migraine
    Diamond, S
    Freitag, FG
    Diamond, ML
    Urban, GJ
    Pepper, BJ
    HEADACHE QUARTERLY-CURRENT TREATMENT AND RESEARCH, 1996, 7 (04): : 326 - 329
  • [27] Effect of Fremanezumab on the Total Burden of Migraine in Patients with Episodic or Chronic Migraine: Findings from 3 Randomized, Double-blind, Placebo-controlled Phase 3 Studies
    Sun-Edelstein, Christina
    Cohen, Joshua M.
    Gandhi, Sanjay K.
    Barash, Steve
    Brandes, Jan Lewis
    NEUROLOGY, 2021, 96 (15)
  • [28] A DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL OF INDOBUFEN IN THE PROPHYLAXIS OF MIGRAINE
    CARRIERI, PB
    OREFICE, G
    SORGE, F
    ACTA NEUROLOGICA SCANDINAVICA, 1988, 77 (06): : 433 - 436
  • [29] A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study
    Yu, Shengyuan
    Kim, Byung-Kun
    Wang, Hebo
    Zhou, Jiying
    Wan, Qi
    Yu, Tingmin
    Lian, Yajun
    Arkuszewski, Michal
    Ecochard, Laurent
    Wen, Shihua
    Yin, Fangfang
    Li, Zheng
    Su, Wendy
    Wang, Shuu-Jiun
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (01):
  • [30] A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study
    Shengyuan Yu
    Byung-Kun Kim
    Hebo Wang
    Jiying Zhou
    Qi Wan
    Tingmin Yu
    Yajun Lian
    Michal Arkuszewski
    Laurent Ecochard
    Shihua Wen
    Fangfang Yin
    Zheng Li
    Wendy Su
    Shuu-Jiun Wang
    The Journal of Headache and Pain, 2022, 23
12345